A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis

Autoimmunity Reviews

Volumn 16, Issue 2, 2017, Pages 179-191

  Misra, Durga Prasanna ^a   Sharma, Aman ^b   Kadhiravan, Tamilarasu ^a   Negi, Vir Singh ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Conventional DMARDs; Cyclophosphamide; Giant cell arteritis; Methotrexate; Mycophenolate mofetil; Takayasu's arteritis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; ANTIRHEUMATIC AGENT;

AORTA ARCH SYNDROME; DRUG EFFICACY; GIANT CELL ARTERITIS; HUMAN; META ANALYSIS; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; PATHOLOGY; PROSPECTIVE STUDY; TAKAYASU ARTERITIS;

ANTIRHEUMATIC AGENTS; GIANT CELL ARTERITIS; HUMANS; PROSPECTIVE STUDIES; TAKAYASU ARTERITIS;

EID: 85009471391     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.12.009     Document Type: Review

References (46)

1. [1] Arend, W.P., Michel, B.A., Bloch, D.A., Hunder, G.G., Calabrese, L.H., Edworthy, S.M., et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33 (1990), 1129–1134.
2. [2] Hunder, G.G., Bloch, D.A., Michel, B.A., Stevens, M.B., Arend, W.P., Calabrese, L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990), 1122–1128.
3. [3] Watts, R.A., Epidemiology of vasculitis in India: what is known?. J Indian Rheumatol Assoc 13 (2005), 8–15.
4. [4] Mukhtyar, C., Guillevin, L., Cid, M.C., Dasgupta, B., de Groot, K., Gross, W., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68 (2009), 318–323.
5. [5] Hoffman, G.S., Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 54 (1996), S99–S102.
6. [6] Cong, X.L., Dai, S.M., Feng, X., Wang, Z.W., Lu, Q.S., Yuan, L.X., et al. Takayasu's arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 29 (2010), 973–981.
7. [7] Borg, F.A., Dasgupta, B., Treatment and outcomes of large vessel arteritis. Best Pract Res Clin Rheumatol 23 (2009), 325–337.
8. [8] Kerr, G.S., Hallahan, C.W., Giordano, J., Leavitt, R.Y., Fauci, A.S., Rottem, M., et al. Takayasu arteritis. Ann Intern Med 120 (1994), 919–929.
9. [9] Aydin, S.Z., Yilmaz, N., Akar, S., Aksu, K., Kamali, S., Yucel, E., et al. Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology (Oxford) 49 (2010), 1889–1893.
10. [10] Misra, R., Danda, D., Rajappa, S.M., Ghosh, A., Gupta, R., Mahendranath, K.M., et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52 (2013), 1795–1801.
11. [11] Direskeneli, H., Aydin, S.Z., Kermani, T.A., Matteson, E.L., Boers, M., Herlyn, K., et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 38 (2011), 1471–1479.
12. [12] Aydin, S.Z., Direskeneli, H., Sreih, A., Alibaz-Oner, F., Gul, A., Kamali, S., et al. Update on outcome measure development for large vessel vasculitis: report from OMERACT 12. J Rheumatol 42 (2015), 2465–2469.
13. [13] Aydin, S.Z., Merkel, P.A., Direskeneli, H., Outcome measures for Takayasu's arteritis. Curr Opin Rheumatol 27 (2015), 32–37.
14. [14] Yilmaz, N., Can, M., Oner, F.A., Kalfa, M., Emmungil, H., Karadag, O., et al. Impaired quality of life, disability and mental health in Takayasu's arteritis. Rheumatology 52 (2013), 1898–1904.
15. [15] Levac, D., Colquhoun, H., O'Brien, K.K., Scoping studies: advancing the methodology. Implement Sci, 5, 2010, 69.
16. [16] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
17. [17] Hoffman, G.S., Leavitt, R.Y., Kerr, G.S., Rottem, M., Sneller, M.C., Fauci, A.S., Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37 (1994), 578–582.
18. [18] Gokhale, Y., Bedmutha, K., Kamble, A., Jadhav, L., P74. Response of Takayasu arteritis (TA) to prednisolone and methotrexate: an open label study. Indian J Rheumatol, 8, 2013, S27 [Abstract].
19. [19] De Souza, A.W.S., Da Silva, M.D., MacHado, L.S.G., Oliveira, A.C.D., Pinheiro, F.A.G., Sato, E.I., Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41 (2012), 227–230.
20. [20] de Souza, A.W.S., de Almeida Agustinelli, R., de Cinque Almeida, H., Oliveira, P.B., Pinheiro, F.A.G., Oliveira, A.C.D., et al. Leflunomide in Takayasu arteritis – a long term observational study. Rev Bras Reumatol Engl Ed 56:4 (Jul-Aug 2016), 371–375.
21. [21] Valsakumar, A.K., Valappil, U.C., Jorapur, V., Garg, N., Nityanand, S., Sinha, N., Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30 (2003), 1793–1798.
22. [22] Shinjo, S.K., Pereira, R.M.R., Tizziani, V.A.P., Radu, A.S., Levy-Neto, M., Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26 (2007), 1871–1875.
23. [23] Daina, E., Schieppati, A., Remuzzi, G., Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 130 (1999), 422–426.
24. [24] Goel, R., Danda, D., Mathew, J., Edwin, N., Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 29 (2010), 329–332.
25. [25] de Franciscis, S., Serra, R., Luongo, A., Sabino, G., Puzziello, A., The management of Takayasu's arteritis: personal experience. Ann Vasc Surg 21 (2007), 754–760.
26. [26] Stern, S., Clemente, G., Reiff, A., Ramos, M.P.R., Marzan, K.A., Terreri, M.T., Treatment of pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study. J Clin Rheumatol 20 (2014), 183–188.
27. [27] Henes, J.C., Müller, M., Pfannenberg, C., Kanz, L., Kötter, I., Cyclophosphamide for large-vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 29 (2011), S43–S48.
28. [28] Hoffman, G.S., Cid, M.C., Hellmann, D.B., Guillevin, L., Stone, J.H., Schousboe, J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002), 1309–1318.
29. [29] Spiera, R.F., Mitnick, H.J., Kupersmith, M., Richmond, M., Spiera, H., Peterson, M.G.E., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001), 495–501.
30. [30] Jover, J.A., Hernández-García, C., Morado, I.C., Vargas, E., Bañares, A., Fernàndez-Gutiérrez, B., Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001), 106–114.
31. [31] Yates, M., Loke, Y.K., Watts, R.A., MacGregor, A.J., Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol 33 (2014), 227–236.
32. [32] Carbonella, A., Berardi, G., Petricca, L., Biscetti, F., Alivernini, S., Bosello, S.L., et al. Immunosuppressive therapy (methotrexate or cyclophosphamide) in combination with corticosteroids in the treatment of giant cell arteritis: comparison with corticosteroids alone. J Am Geriatr Soc 64 (2016), 672–674.
33. [33] Hernández-García, C., Soriano, C., Morado, C., Ramos, P., Fernández-Gutiérrez, B., Herrero, M., et al. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol 23 (1994), 295–298.
34. [34] Koster, M.J., Crowson, C., Labarca, C., Muratore, F., Warrington, K.J., Efficacy of methotrexate in giant cell arteritis. Ann Rheum Dis, 75(Suppl. 2), 2016, 796 [Abstract].
35. [35] Sailler, L., Lapeyre-Mestre, M., Geffray, L., Letellier, P., Liozon, E., De La Roque, P.M., et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial. Arthritis Rheum, 60(Suppl. 10), 2009, 1972 [Abstract].
36. [36] Adizie, T., Christidis, D., Dharmapaliah, C., Borg, F., Dasgupta, B., Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract 66 (2012), 906–909.
37. [37] Diamantopoulos, A.P., Hetland, H., Myklebust, G., Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int, 2013, 2013.
38. [38] De Silva, M., Hazleman, B.L., Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986), 136–138.
39. [39] Sciascia, S., Piras, D., Baldovino, S., Russo, A., Naretto, C., Rossi, D., et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res 24 (2012), 273–277.
40. [40] Dospinescu, P.I., Karabayas, M., Kidder, D., Fluck, N., Erwig, L., Mason, J., et al. Mycophenolate mofetil versus methotrexate in the management of large vessel giant cell arteritis. Ann Rheum Dis, 75(Suppl. 2), 2016, 798 [Abstract].
41. [41] Quartuccio, L., Maset, M., De maglio, G., Pontarini, E., Fabris, M., Mansutti, E., et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 51 (2012), 1677–1686.
42. [42] Loock, J., Henes, J., Kötter, I., Witte, T., Lamprecht, P., Schirmer, M., et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 30 (2012), S70–S76.
43. [43] de Boysson, H., Boutemy, J., Creveuil, C., Ollivier, Y., Letellier, P., Pagnoux, C., et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 43 (2013), 105–112.
44. [44] Ly, K., Liozon, E., Fauchais, A., Bezanahary, H., Rhaiem, K., Loustaud Ratti, V., et al. Dapsone in giant cell arteritis: a retrospective study of 45 patients. Ann Rheum Dis, 67(Suppl. II), 2008, 359 [Abstract].
45. [45] Schaufelberger, C., Andersson, R., Nordborg, E., No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37 (1998), 464–465.
46. [46] Ly, K., Liozon, E., Fauchais, A., Bezanahary, H., Rhaiem, K., Loustaud Ratti, V., et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35 (2006), 327–329.